Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

GeoVax Labs, Inc.

NASDAQ: GOVX · Life Sciences · 6 alerts · CIK 832489

Share price
$2.02Close, Nov 16
Market cap
$1.1M
Shares outstanding
544.45KLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All GeoVax Labs, Inc. filings on SEC EDGAR ↗

4:03 PM ET 10-Q
Financial Results

GeoVax Labs Q3 2026 Results: Net Loss of $4.16M, Loss Narrows

GeoVax Labs, Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $17.0 million in the prior year period. The company is prioritizing its GEO-MVA vaccine candidate for poxviruses and its Gedeptin oncology program, though both require additional financing to initiate upcoming Phase 3 and Phase 2 trials, respectively.

Key figure
Net loss $4.16M
6:12 AM ET 8-K
Reverse Stock Split

GeoVax Labs Reverse Stock Split

GeoVax Labs, Inc. filed a Certificate of Amendment to its Certificate of Incorporation to effect a 1-for-24 reverse stock split of its common stock. The split automatically combines every 24 shares of issued and outstanding common stock into one share, with fractional shares rounded up to the nearest whole number. The action is intended to consolidate the number of outstanding shares without changing the proportional ownership interest of stockholders.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.